{
  "abstract": "Background The safety and clinical impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with ­chronic pancreatitis (CP) without diabetes are uncertain. We evaluated whether GLP-1 RA exposure was associated with pancreatic, oncologic, healthcare-utilization, and other clinical outcomes in non-diabetic adults with CP.Methods We performed a retrospective propensity score–matched cohort study using the TriNetX Collaborative Network (68 healthcare organizations). Adults with CP and no type 1 or type 2 diabetes were identified. The exposed cohort included patients receiving dulaglutide, semaglutide, or tirzepatide (n=1,440 before matching), and the comparator cohort included patients with CP without GLP-1 RA exposure (n=142,026 before matching). One-to-one propensity score matching generated 1,422 patients in each cohort. Outcomes were assessed from 1 to 1,095 days after index.Results After matching, baseline covariates were well balanced (all standardized mean differences <0.1). GLP-1 RA exposure was associated with lower risk of recurrent acute pancreatitis (2.4% vs 10.8%; HR 0.247, 95% CI 0.149–0.409), pancreatic cancer (0.7% vs 3.0%; HR 0.255, 95% CI 0.128–0.511), composite gastrointestinal cancers (1.0% vs 3.5%; HR 0.326, 95% CI 0.179–0.596), and all-cause mortality (1.5% vs 11.1%; HR 0.167, 95% CI 0.105–0.263). GLP-1 RA use was also associated with fewer emergency room visits (7.4% vs 19.7%; HR 0.441, 95% CI 0.311–0.626), hospitalizations (7.0% vs 19.5%; HR 0.428, 95% CI 0.298–0.615), ERCP procedures (0.8% vs 5.5%; HR 0.166, 95% CI 0.088–0.313), chronic opioid prescriptions (2.6% vs 6.1%; HR 0.522, 95% CI 0.338–0.804), insulin initiation (2.6% vs 9.3%; HR 0.322, 95% CI 0.216–0.480), hypoglycemia (0.9% vs 2.8%; HR 0.438, 95% CI 0.227–0.846), malnutrition (1.0% vs 8.5%; HR 0.136, 95% CI 0.076–0.242), anemia (5.5% vs 15.2%; HR 0.431, 95% CI 0.310–0.601), and acute kidney injury (2.1% vs 6.9%; HR 0.402, 95% CI 0.255–0.633). Vitamin D deficiency was the only outcome with a higher hazard in the GLP-1 RA group (HR 1.556, 95% CI 1.129–2.145). ( IDDF2026-ABS-0341 Figure 1. Forest plot for hazard ratios of clinical outcomes)Conclusions In this study of non-diabetic adults with CP, GLP-1 RA exposure was associated with lower risks of recurrent acute pancreatitis, pancreatic and GI cancers, mortality, healthcare utilization, and several other adverse clinical outcomes, although vitamin D deficiency occurred more often.Abstract IDDF2026-ABS-0341 Figure 1",
  "authors": [
    {
      "affiliations": [
        "Sheffield Teaching Hospitals NHS Foundation Trust, United Kingdom"
      ],
      "name": "Arkadeep Dhali"
    },
    {
      "affiliations": [
        "Roswell Park Comprehensive Cancer Center, United States"
      ],
      "name": "Fayaz Khan"
    }
  ],
  "title": "IDDF2026-ABS-0341 GLP-1 receptor agonists and clinical outcomes in non-diabetic patients with chronic pancreatitis: a real world cohort study",
  "uid": "68bedff2-018f-58a4-bdae-36ac1d97e3cf"
}